Urifron is named as an intervention in 4 current clinical trials in our Canada, Mexico, Israel and Ireland registers. None are recruiting at the moment. All registered phases are Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (3). The most-studied condition is Clinical Stage III Cutaneous Melanoma AJCC v8.
Of the three regulators tracked here, the first to approve Urifron was the US, on 4 Jun 1986. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Clinical Stage III Cutaneous Melanoma AJCC v8 | 1 |
| Clinical Stage IV Cutaneous Melanoma AJCC v8 | 1 |
| Metastatic Cutaneous Melanoma | 1 |
| Metastatic Mucosal Melanoma | 1 |
| Melanoma of Unknown Primary | 1 |
| Recurrent Melanoma | 1 |
| Stage IIIB Cutaneous Melanoma AJCC v7 | 1 |
| Stage IIIC Cutaneous Melanoma AJCC v7 | 1 |
| Colorectal Neuroendocrine Tumor G1 | 1 |
| Gastric Neuroendocrine Tumor G1 | 1 |
| Neuroendocrine Neoplasm | 1 |
| Neuroendocrine Tumor | 1 |
| Melanoma (Skin) | 1 |
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| ECOG-ACRIN Cancer Research Group | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 0 |
| Clinical trials in Mexico | 3 | 0 |
| Clinical trials in Israel | 3 | 0 |
| Clinical trials in Ireland | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our Canada, Mexico, Israel and Ireland registers name Urifron (also registered as Recombinant Interferon Alfa-2b) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 4 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
National Cancer Institute (NCI) (3) and ECOG-ACRIN Cancer Research Group (1). The number in brackets is how many trials each organisation leads.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Urifron works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Urifron works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Urifron (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.